Healthcare Industry News:  EndoGastric Solutions 

Devices Surgery

 News Release - August 18, 2008

EndoGastric Solutions Approaches 1,500 Completed Natural Orifice Surgery (NOS) Cases

NOS Procedures Continue to Gain Momentum Worldwide

REDWOOD CITY, Calif.--(HSMN NewsFeed)--EndoGastric Solutions (EGS), the recognized leader in the emerging field of Natural Orifice Surgery (NOS), today announced that nearly 1,500 incisionless NOS procedures have been successfully completed in the United States, Europe and Brazil with its innovative NOS surgical devices.

“This is a significant milestone for EndoGastric Solutions and is an indicator that NOS is gaining momentum both with surgeons and with patients,” said Thierry Thaure, President and Chief Executive Officer of EndoGastric Solutions. “In fact, more than 95% of all NOS procedures of the GI tract being performed today are performed using EGS devices, illustrating how we are driving adoption of what is widely regarded as the future of surgery. Patient demand continues to grow, as does national media coverage of our products and the procedures they are being used to perform. Millions of patients worldwide can benefit from these incisionless surgical procedures. EGS has seen procedure volume double in the last few months, and we anticipate continued dramatic growth over the next few years,” he added.

EGS has developed a proprietary NOS platform technology. StomaphyX® and EsophyX®, EGS’ first two NOS surgical devices, are designed specially for performing incisionless reconstructive gastrointestinal procedures. The devices are introduced into the body through the mouth, rather than through an abdominal incision. The advantages of incisionless surgery over laparoscopic or open surgery include shorter hospital stay, reduced patient discomfort, shortened patient recovery, no visible scars, and typically higher patient satisfaction.

With StomaphyX, under visual guidance of an endoscope, small sections of the stomach wall are suctioned into the device and fastened with permanent suture-like fasteners to create multiple large tissue folds, or plications. Multiple plications can be created depending on the needs of the patient. The EsophyX TIF procedure reconstructs a robust antireflux barrier at the gastroesophageal junction, using a similar procedure, restoring natural anatomical geometry to effectively treat Gastroesophageal Reflux Disease (GERD).

“NOS procedures like EGS’ EsophyX TIF procedure for treating GERD are gaining popularity because they emulate proven surgical principles using a completely transoral approach,” said Nathaniel Soper, M.D., Professor and Chair of Surgery at Northwestern University Feinberg School of Medicine and one of the first surgeons in the United States to perform NOTES (Natural Orifice Translumenal Endoscopic Surgery) procedures. “We are performing surgery from within, completely without external incisions or internal dissection. EGS’ NOS devices are the first commercially available incisionless surgical tools to provide durable results that approximate those of laparoscopic surgical procedures.”

The Ohio State University Medical Center of Columbus, Ohio, was the first site in the U.S. to perform a NOS procedure with EGS’ devices. “We performed the first StomaphyX procedures in April of 2007 and began using the EsophyX TIF procedure for the treatment of GERD as soon as it was FDA cleared in late 2007,” said Scott Melvin, M.D., Professor of Surgery at The Ohio State University Center for Minimally Invasive Surgery. “We have performed more than 100 NOS cases to date and our patients are doing well. We have had no serious complications and our results have been comparable to more invasive laparoscopic procedures. Surgeons performing NOS procedures are helping to pioneer the future of surgery, and we’re proud to be on the forefront of that effort,” he concluded.

About EndoGastric Solutions

EndoGastric Solutions (EGS) is a privately held corporation located in Redmond, Washington, and Redwood City, California. EGS is a pioneer in developing incisionless transoral procedures for the treatment of upper gastrointestinal conditions, including gastroesophageal reflux disease (GERD) and other GI conditions. EsophyX® and StomaphyX® are cleared by the FDA, CE marked, and available for sale in the U.S. and other parts of the world.

For more information about EndoGastric Solutions, Inc., EsophyX and StomaphyX, please visit:



Other locations:

Source: EndoGastric Solutions

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.